As new biosimilars enter the market, pharmacies should carefully consider infrastructure, resources, and strategies for successfully integrating the products into their portfolio of offerings.
T. Mitchell James, III
Advertisement
Articles by T. Mitchell James, III
Advertisement
Latest Updated Articles
Not Just a Generic: Specialty Pharmacy Considerations for a Biosimilar LaunchPublished: June 2nd 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
2
Under Pressure: A Brief Overview of the Updated Hypertension Guidelines
3
Biosimilar Stivant Shows Noninferior Efficacy and Comparable Safety to Reference Bevacizumab
4
Current and Emerging BCMAxCD3 Bispecifics
5
